Plain-English translation of NCT05784246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing mirikizumab, a new medication designed to treat moderate to severe ulcerative colitis in children and teenagers ages 2 to 17. The medication works by calming the immune system's overactive response in the gut. Researchers want to see if this treatment can reduce symptoms and help kids feel better when other medications haven't worked.
Ulcerative colitis can cause severe pain, bleeding, and other serious complications in children, and some kids don't respond well to existing treatments. This study exists to find out if this medication could offer hope to young patients whose symptoms aren't controlled by current options.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive the new medication by injection—either under the skin or through an IV—with doses adjusted based on your weight. You'll come to clinic visits so doctors can check how you're responding, monitor for any side effects, and take blood samples. After finishing the main study, you'll have the option to continue in a longer-term follow-up study to see how the treatment works over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States